IMPACT Therapeutics focuses on developing anti-cancer therapeutics and advancing a pipeline of oncology drug candidates. The company is China-based and uses equity financings to fund its development programs. It completed a Series D+ funding round of 400 million yuan (about $55.2 million) to support progress across its pipeline. The proceeds are intended to advance its cancer therapeutics programs toward further development. The article did not disclose any operating metrics such as revenue or user numbers. No investors were named in the coverage provided. IMPACT Therapeutics develops targeted anti-cancer therapeutics grounded in synthetic lethality and has assembled a broad DNA damage response (DDR) pipeline. Its pipeline includes PARP inhibitor Senaparib (IMP4297), Wee1 inhibitor IMP7068, ATR inhibitor IMP9064 and other DDR pathway inhibitors, with three synthetic lethality compounds in the clinical stage. Senaparib (IMP4297) is in Phase II/III studies for ovarian, prostate, small cell lung cancer and other indications worldwide, and preliminary clinical data demonstrated superior tolerability and a wider therapeutic window versus other PARP inhibitors. Phase I studies for IMP7068 and IMP9064 are underway globally and in several countries respectively, and Hedgehog pathway inhibitor IMP5471 has received IND approval from China's NMPA to initiate clinical studies. In 2021 the company reported breakthroughs on multiple targets including PARP, Wee1, and ATR and is expanding to other novel synthetic lethality targets to broaden its pipeline. The company said proceeds from a recently closed Series D1 financing will be used to accelerate development of its synthetic lethality programs, many of which it believes have best-in-class potential. Management expressed confidence in implementing a global development strategy and advancing clinical trials at full speed following the financing. Impact Therapeutics is a clinical-stage biopharmaceutical company based in Nanjing, China focused on discovery and development of therapeutics for cancer and other life‑threatening diseases. Its lead program is IMP4297, a potential best‑in‑class PARP inhibitor currently undergoing Phase I trials in Australia and China. IMP4297 has demonstrated a favorable safety profile and promising preliminary efficacy in those Phase I studies, consistent with preclinical data showing high potency and a large therapeutic window. The company also advances integrated programs targeting the DNA damage response (DDR). Impact plans to use new financing to support clinical development of IMP4297 and to advance its DDR pipeline. The company leadership includes CEO Dr. Ye Edward Tian and SVP/CTO Dr. Sui Xiong Cai. Impact Therapeutics is a Nanjing, China–based company dedicated to the discovery, development and commercialization of novel therapeutics to treat cancer and other life-threatening diseases. Led by Dr. Edward Tian (CEO) and Dr. Sui Xiong Cai (SVP and CTO), the company has established a research and business platform using methods for the discovery and development of novel anti-cancer drugs. It has several anti-tumor drug projects in preclinical and clinical stages and submitted a class 1.1 drug IND application in December 2015. Impact intends to use newly raised funds to advance clinical studies and its pipeline products. The company previously closed a Series A in July 2014 led by Lilly Asia Ventures, Cenova Capital and Wuxi AppTec Ventures. Financially, it secured around $10m in a Series B financing to support ongoing development.

Total raised

$95M

Funding rounds

4

Latest round

Series D

Latest activity

Apr 2024